PMID- 23885167
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130725
LR  - 20211021
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 7
DP  - 2013
TI  - Incidence of deepening of upper eyelid sulcus after topical use of tafluprost 
      ophthalmic solution in Japanese patients.
PG  - 1441-6
LID - 10.2147/OPTH.S47783 [doi]
AB  - PURPOSE: To investigate the incidence of deepening of upper eyelid sulcus (DUES) 
      with topical use of tafluprost in Japanese glaucoma patients. METHODS: This study 
      was a prospective, open-label, non-controlled case series conducted at a single 
      center. Thirty-six primary open-angle glaucoma Japanese patients who had no 
      history of surgery were enrolled. The patients were prescribed 0.0015% topical 
      tafluprost once daily to one eye that had the more severe visual field disorder, 
      and observed during outpatient visits before and at 30, 60, and 90 days after 
      starting treatment. At every visit, three examiners judged the presence of DUES 
      unanimously by facial photographs including eyebrows and lower eyelids. The 
      primary outcome variable was the incidence of DUES at the end of day 90 in the 
      study as assessed by observer-masked facial photography. The patients were also 
      asked if they noticed any subjective symptom of DUES. Gender, refraction, and 
      intraocular pressure were evaluated as potential risk factors. RESULTS: 
      Thirty-two patients completed this clinical trial. DUES were identified 
      objectively in 19% (6/32) of the patients after 90 days of treatment. The 
      incidence was not related to gender, refraction, baseline or post-treatment 
      intraocular pressure, or intraocular pressure reduction. Finally, 17% (1/6) of 
      patients with objectively diagnosed DUES noticed the presence of DUES by 
      themselves. No patient dropped out of the study because of DUES. CONCLUSION: 
      Similar to other prostaglandin analogs, topical use of tafluprost ophthalmic 
      solution is associated with DUES as a local adverse reaction.
FAU - Maruyama, Katsuhiko
AU  - Maruyama K
AD  - Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.
FAU - Tsuchisaka, Asako
AU  - Tsuchisaka A
FAU - Sakamoto, Jumpei
AU  - Sakamoto J
FAU - Shirato, Shiroaki
AU  - Shirato S
FAU - Goto, Hiroshi
AU  - Goto H
LA  - eng
PT  - Journal Article
DEP - 20130715
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC3716560
OTO - NOTNLM
OT  - deepening
OT  - eyelid
OT  - prostaglandins
OT  - side effect
OT  - tafluprost
EDAT- 2013/07/26 06:00
MHDA- 2013/07/26 06:01
PMCR- 2013/07/15
CRDT- 2013/07/26 06:00
PHST- 2013/07/26 06:00 [entrez]
PHST- 2013/07/26 06:00 [pubmed]
PHST- 2013/07/26 06:01 [medline]
PHST- 2013/07/15 00:00 [pmc-release]
AID - opth-7-1441 [pii]
AID - 10.2147/OPTH.S47783 [doi]
PST - ppublish
SO  - Clin Ophthalmol. 2013;7:1441-6. doi: 10.2147/OPTH.S47783. Epub 2013 Jul 15.